How to Get Evenity (Romosozumab) in Delaware

What Is Romosozumab and Why Does Access Matter?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates new bone formation and reduces bone resorption. No other approved osteoporosis drug produces this dual effect.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone over 24 months. In the FRAME trial (N=7,180), romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months. These results positioned the drug as a first-line anabolic option for patients at very high fracture risk, per the 2020 Endocrine Society clinical practice guideline.

Access in Delaware follows a structured but navigable path. The state permits telehealth prescribing, Medicaid covers the drug with prior authorization, and both specialty and 503A compounding pharmacies can fill or compound sclerostin-inhibitor prescriptions. The steps below walk through each stage of the process.

Step 1: Find a Qualified Prescriber in Delaware

Any physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) licensed in Delaware can prescribe Evenity, provided the prescription falls within their scope of practice. In practice, most romosozumab prescriptions originate from endocrinologists, rheumatologists, or orthopedic specialists who manage osteoporosis.

Delaware permits full practice authority for nurse practitioners under Title 24, Chapter 19 of the Delaware Code. This means NPs in Delaware can independently evaluate, diagnose, and prescribe without a collaborative agreement with a physician. PAs in Delaware prescribe under a collaborative agreement with their supervising physician.

For patients in rural Sussex or Kent counties where specialist density is lower, telehealth removes the geographic barrier. Delaware's telehealth parity law (Senate Bill 32, signed 2015, updated 2020) requires that private insurers reimburse telehealth visits at the same rate as in-person care. A board-certified endocrinologist licensed in Delaware can evaluate you via video, order labs, and write the prescription without requiring an in-person visit for the initial consultation.

Three practical routes to a prescriber:

1. Referral from your primary care provider. Ask for a referral to an endocrinologist or rheumatologist with osteoporosis experience. Christiana Care, Bayhealth, and Beebe Healthcare all have bone health programs.
2. Telehealth platforms. Several national telehealth services employ Delaware-licensed endocrinologists. Confirm the provider has experience with anabolic osteoporosis agents before booking.
3. HealthRX consultation. Our medical team can evaluate whether romosozumab is appropriate and coordinate the prescription, labs, and prior authorization process within Delaware.

Step 2: Complete the Required Labs and Screening

Romosozumab carries an FDA black box warning for increased cardiovascular risk, including myocardial infarction and stroke. Before prescribing, your provider must confirm you are not at prohibitive cardiovascular risk, and that your bone density and fracture history justify an anabolic agent.

Baseline labs typically include:

• DEXA scan (dual-energy X-ray absorptiometry). A T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip confirms osteoporosis. Most insurers require a DEXA within the past 24 months for prior authorization.
• Serum calcium. Hypocalcemia must be corrected before starting romosozumab. The Endocrine Society guideline recommends verifying calcium levels are within normal range (8.5 to 10.5 mg/dL).
• 25-hydroxyvitamin D. Levels should be above 30 ng/mL. Patients with insufficiency (<30 ng/mL) should supplement before treatment begins.
• Comprehensive metabolic panel (CMP). Evaluates kidney function (eGFR) and liver enzymes.
• Cardiovascular risk assessment. At minimum, a review of blood pressure, lipid panel, and cardiac history. Patients with a history of MI or stroke within the preceding 12 months are contraindicated per the FDA label. Your provider may order an ECG or refer for cardiac clearance if risk factors are present.

Delaware has multiple Quest Diagnostics and Labcorp locations in New Castle, Kent, and Sussex counties. Mobile phlebotomy services are also available for homebound patients. DEXA scans are offered at most hospital imaging centers and several freestanding radiology practices across the state.

Step 3: Manage Prior Authorization in Delaware

Almost every commercial insurer and Delaware Medicaid requires prior authorization (PA) for Evenity. The drug costs approximately $1,825 per injection at wholesale acquisition cost, which makes PA a near-universal gatekeeper.

What documentation insurers typically require:

• A DEXA scan showing a T-score of -2.5 or below, or a T-score between -1.0 and -2.5 with a prior fragility fracture
• Documentation of prior fracture history (vertebral, hip, or other fragility fracture)
• Evidence that bisphosphonates failed, were not tolerated, or are contraindicated. Some insurers accept high FRAX score (10-year major osteoporotic fracture probability of 20% or higher) as standalone justification
• Confirmation that the patient has no history of MI or stroke in the past 12 months
• Prescriber notes supporting very high fracture risk

Delaware Medicaid covers romosozumab with PA for severe osteoporosis. The state uses the American Association of Clinical Endocrinology (AACE) 2020 guidelines as its clinical framework, which recommend anabolic therapy first for patients at very high fracture risk rather than starting with antiresorptives.

PA turnaround varies. Commercial insurers in Delaware typically respond within 5 to 10 business days. Urgent or expedited requests (for example, after a recent fracture) may receive a decision within 72 hours. If denied, your prescriber can file a peer-to-peer review or a formal appeal. The denial letter will include specific appeal instructions and timelines under Delaware insurance regulations.

A 2022 retrospective analysis found that roughly 40% of initial PA requests for romosozumab are denied across commercial payers, but approximately 60% to 70% of appeals succeed when additional clinical documentation is submitted (Salmasi et al., 2022). Persistence matters.

Step 4: Fill the Prescription at a Delaware Pharmacy

Evenity is a specialty medication. It will not be stocked at a typical retail pharmacy. You have several options in Delaware:

Specialty pharmacies. Most large health systems in Delaware (Christiana Care, Bayhealth) have affiliated specialty pharmacies that stock Evenity. National specialty pharmacies like Accredo, BriovaRx, and CVS Specialty can also ship to Delaware addresses. These pharmacies handle cold-chain storage, patient education, and coordination with your insurer.

503A compounding pharmacies. Delaware-licensed 503A compounding pharmacies can compound patient-specific prescriptions. However, romosozumab is a biologic monoclonal antibody, which makes traditional compounding impractical. 503A pharmacies may assist with ancillary needs (calcium and vitamin D formulations, for example) but the romosozumab itself will come from Amgen's supply chain through a specialty pharmacy.

Administration. Each Evenity dose is delivered as two subcutaneous injections of 105 mg each (given consecutively at separate injection sites). The injections are administered by a healthcare provider in a clinical setting. They cannot be self-administered at home. Your prescriber's office, an infusion center, or a nurse visit service will handle the monthly injections. Each visit takes roughly 15 to 30 minutes.

Cost, Insurance, and Financial Assistance

The full 12-month course of Evenity costs approximately $21,900 at list price. Out-of-pocket costs depend heavily on insurance coverage.

Medicare Part B covers Evenity when administered in a physician's office or outpatient setting (it falls under the medical benefit, not the pharmacy benefit). Patients typically owe 20% coinsurance after the Part B deductible, which can amount to $4,000 or more without supplemental coverage.

Commercial insurance copays vary. With prior authorization approved, many plans set a specialty tier copay of $100 to $500 per injection, though some high-deductible plans may expose patients to full cost until the deductible is met.

Amgen's Evenity copay assistance program covers up to $15,000 per year in out-of-pocket costs for commercially insured patients. This program can reduce monthly copays to as low as $0 to $5 per injection. It is not available to patients on government insurance (Medicare, Medicaid, Tricare).

For uninsured or underinsured patients, Amgen's Safety Net Foundation provides Evenity at no cost to qualifying individuals with household incomes below 300% of the federal poverty level. Application requires income documentation and a completed enrollment form from the prescriber.

The AACE 2020 guideline emphasizes that cost should not prevent access to anabolic therapy in very-high-risk patients, and recommends that clinicians actively assist with financial navigation.

Clinical Considerations: Who Should (and Should Not) Get Romosozumab

Romosozumab is FDA-approved for postmenopausal women with osteoporosis at high risk for fracture. "High risk" is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies.

The drug is contraindicated in patients with:

• A history of myocardial infarction or stroke within the preceding 12 months
• Hypocalcemia (must be corrected before initiation)
• Known hypersensitivity to romosozumab or any component of the formulation

The ARCH trial showed a numerically higher rate of serious cardiovascular events with romosozumab versus alendronate (2.5% vs. 1.9% at 12 months), which prompted the black box warning. Patients with additional cardiovascular risk factors (uncontrolled hypertension, diabetes, smoking, hyperlipidemia) should undergo thorough cardiovascular evaluation before starting treatment.

Off-label use in men with osteoporosis and in glucocorticoid-induced osteoporosis is growing, though the BRIDGE trial (which studied romosozumab in men) led to FDA approval for men in some international markets. In the U.S., prescribers may use clinical judgment for off-label male osteoporosis cases. Delaware law does not restrict off-label prescribing by licensed providers.

What Happens After the 12-Month Course

Romosozumab is a fixed-duration therapy. After completing 12 monthly injections, bone density gains begin to decline unless a follow-up antiresorptive agent is started.

The standard sequence, supported by ARCH trial data: romosozumab for 12 months, then transition to a bisphosphonate (alendronate or zoledronic acid) or denosumab. This "anabolic first, antiresorptive second" approach produced a 48% relative risk reduction in new vertebral fractures compared with alendronate monotherapy at 24 months.

A post-hoc analysis of the FRAME extension found that patients who received romosozumab followed by denosumab continued gaining bone density through month 36, with lumbar spine BMD increasing by 17.6% from baseline (Cosman et al., 2018). The choice of follow-on agent depends on fracture risk severity, renal function, and patient preference.

Your Delaware provider should plan the transition therapy before you complete the final romosozumab injection. Do not stop treatment without a follow-on plan, as the bone-forming window closes rapidly once romosozumab is discontinued.

Timeline: From First Appointment to First Injection

Here is a realistic timeline for a Delaware patient starting from scratch:

| Step | Estimated Time | |---|---| | Initial consultation (in-person or telehealth) | Week 1 | | Labs drawn and DEXA scan completed | Weeks 1 to 2 | | Lab results reviewed, prescription written | Week 2 to 3 | | Prior authorization submitted | Week 3 | | PA decision received | Weeks 3 to 5 | | Specialty pharmacy ships or stocks Evenity | Weeks 4 to 6 | | First injection administered | Weeks 4 to 6 |

Total time from initial visit to first injection: 4 to 6 weeks in most cases. Delays in prior authorization (especially denials requiring appeal) can extend this to 8 to 12 weeks. Patients with recent fractures may qualify for expedited PA processing.